financetom
Business
financetom
/
Business
/
Boeing Faces Weaker 2024 Cash Outlook; 'Long-Term Positives' Offer Hope, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Boeing Faces Weaker 2024 Cash Outlook; 'Long-Term Positives' Offer Hope, UBS Says
Aug 1, 2024 1:15 PM

03:47 PM EDT, 08/01/2024 (MT Newswires) -- Boeing's ( BA ) cash outlook for 2024 is weaker, but several "long-term positives" counterbalance this, UBS Securities said in a note Thursday.

The plane maker expects a $3.3 billion cash burn in Q3, reflecting a portion of the $1 billion Defense charge in the quarter, before achieving a positive free cash flow of $5.2 billion in Q4, according to the note.

"[While] H2 still has some clear risks, we believe Boeing ( BA ) is on the verge of returning to meaningful positive [free cash flow] generation which we see growing through 2028 and likely beyond," UBS said.

Risks in H2 include completing rework, managing capital and liquidity and avoiding strikes. While wage inflation is minimal, a work stoppage could impact all these factors, UBS said.

"With a new CEO announced and a tangible update on MAX factory progress, we feel increasingly confident that Boeing ( BA ) is positioned for a sustained recovery in production rates," UBS said, adding that Kelly Ortberg will become chief executive of the company, starting Aug. 8.

UBS maintained a buy rating on Boeing ( BA ) with a 12-month price target of $240.

Price: 177.06, Change: -13.54, Percent Change: -7.10

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Royalty Pharma Buys Royalty Interest in Alnylam Pharmaceuticals' Amvuttra From Blackstone Life Sciences for $310 Million
Royalty Pharma Buys Royalty Interest in Alnylam Pharmaceuticals' Amvuttra From Blackstone Life Sciences for $310 Million
Nov 4, 2025
11:34 AM EST, 11/04/2025 (MT Newswires) -- Royalty Pharma ( RPRX ) said Tuesday it has acquired a royalty interest in Alnylam Pharmaceuticals' ( ALNY ) Amvuttra from Blackstone (BX) Life Sciences-managed funds for $310 million. Royalty Pharma ( RPRX ) said it acquired Blackstone's 1% royalty on global net sales of Amvuttra, a treatment of a disease caused by...
Palmer Johnson Power Systems Acquires WHECO Los Angeles Location
Palmer Johnson Power Systems Acquires WHECO Los Angeles Location
Nov 4, 2025
Expanding Capabilities and Strengthening Service Reach in Southern California MADISON, Wis., Nov. 4, 2025 /PRNewswire/ -- Palmer Johnson Power Systems (PJPS), a leading distributor and service provider of off-highway powertrain solutions, is proud to announce the acquisition of the WHECO Los Angeles, CA location. This strategic expansion strengthens PJPS's presence on the West Coast, enhancing capabilities and expanding reach to...
BRIEF-Joss Realty REIT Expect IPO Price Of Common Stock To Be Between $4.00 & $6.00 Per Share
BRIEF-Joss Realty REIT Expect IPO Price Of Common Stock To Be Between $4.00 & $6.00 Per Share
Nov 4, 2025
Nov 4 (Reuters) - JOSS Realty REIT Inc: * JOSS REALTY REIT, INC - EXPECT IPO PRICE OF COMMON STOCK TO BE BETWEEN $4.00 AND $6.00 PER SHARE * JOSS REALTY REIT, INC - HAVE APPLIED TO LIST COMMON STOCK ON NYSE AMERICAN LLC UNDER THE SYMBOL JOSS. * JOSS REALTY REIT INC: FILES FOR IPO OF 3 MILLION SHARES...
Datadog Well-Positioned for Market Share Gains, Set for Strong Q3 Results, Wedbush Says
Datadog Well-Positioned for Market Share Gains, Set for Strong Q3 Results, Wedbush Says
Nov 4, 2025
11:35 AM EST, 11/04/2025 (MT Newswires) -- Datadog ( DDOG ) is well-positioned to keep gaining market share in the observability space and is expected to deliver another strong Q3 report on Thursday, Wedbush Securities said in a Tuesday note. Based on our recent checks, we believe that DDOG is coming away as a larger winner within the observability sector...
Copyright 2023-2026 - www.financetom.com All Rights Reserved